Differences in survivin location and Bcl-2 expression in CD30+ lymphoproliferative disorders of the skin compared with systemic anaplastic large cell lymphomas: an immunohistochemical study

$48.00 plus tax (Refund Policy)

Download / Buy Article:

Abstract:

Summary Background 

Cutaneous CD30+ lymphoproliferative disorders (LPDs) are a spectrum of disease associated with a favourable prognosis. Systemic anaplastic large cell lymphoma (ALCL), although morphologically and phenotypically similar, differs in clinical presentation and has a less favourable biological behaviour. Dysregulation of apoptosis, the process regulating cell population by programmed death, can explain the differences among these disorders. Objectives 

We investigated the expression of two inhibitors of apoptosis, survivin and Bcl-2 protein, in serial skin lesion samples from CD30+ LPDs compared with systemic ALCL. Methods 

Immunohistochemical analysis with antibodies against anaplastic lymphoma kinase (ALK)-1 protein, survivin and Bcl-2 protein was performed in 10 cutaneous CD30+ LPDs (five lymphomatoid papulosis, five ALCL) and 18 systemic ALCLs. Reverse transcription–polymerase chain reaction studies for ALK and ALK/nucleophosmin were also performed. Results 

Cutaneous CD30+ LPDs shared a heterogeneous expression of cytoplasmic survivin with all systemic ALCLs, and of Bcl-2 with systemic ALK− ALCLs; however, they differ from systemic ALK− ALCLs because they lack nuclear survivin (P = 0·045), and from systemic ALK+ ALCLs by a higher expression of Bcl-2 (P = 0·045) and a lack of ALK-1. Overall, coexpression of Bcl-2 and nuclear survivin in CD30+ LPDs was associated with a less favourable disease survival. Conclusions 

The different patterns of expression of Bcl-2 and survivin in CD30+ LPDs might have an impact on their different biological and clinical behaviour. Moreover, nuclear localization of survivin, similarly to ALK, may be a useful marker for predicting a systemic form of ALCL with cutaneous presentation.

Keywords: Bcl-2; CD30+ lymphoproliferative disorders; anaplastic large cell lymphoma; anaplastic lymphoma kinase; survivin

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1365-2133.2007.07933.x

Affiliations: 1: Clinic of Dermatology, 2: Clinic of Hematology 3: Laboratory of Cellular and Molecular Biology, Institute of Clinical Medicine and Applied Biotechnologies, Polytechnic University of Marche Region, Via Conca 71, 60020 Torrette di Ancona, Ancona, Italy 4: Department of Surgical Sciences, University of Foggia, Foggia, Italy

Publication date: July 1, 2007

Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more